The cookie settings on this website are set to 'allow all cookies' to give you the very best experience. Please click Accept Cookies to continue to use the site.

Test With Confidence: Research Drug Monitoring

Oct 1st 2021

Our Research Drug Monitoring ELISA Kits are highly sensitive and specific assay tests for determining the concentration of Adalimumab, Infliximab, Rituximab,Tocilizumab and many more in serum and plasma.

The Research Drug Monitoring ELISA Assay Kits can be used for university research, pharmaceutical research, or clinical research. Each kit comes with specialized instructions regarding the incubation time required, dynamic range, sample type, as well as kit reagent contents. These are very useful ELISA test kits for the measurement of drugs (antibodies against TNF-alpha and others) and the antibody against these drugs (ATI and others) all developed by a senior immunology professor from our partner's scientific team. Development is underway of more products of this group in order to keep pace with the ongoing development of new drugs.

Below we spotlight our Tocilizumab ELISA (mAb-based) Cat #TM09021, a double-monoclonal antibody enzyme immunoassay for the quantitative determination of free Tocilizumab in human serum and plasma.

  • The most specific kit in the market by the advantage of using monoclonal antibodies for coating the wells (capture-mab) and in the conjugate (tracer-mab) specific to Tocilizumab (Actemra) only.
  • Measures only the free form of Tocilizumab (not Tocilizumab molecules that are already bound to IL-6 Receptor or anti-Tocilizumab-antibodies).
  • Efficient monitoring of Tocilizumab serum level during therapy is essential for the subject's follow-up.
  • Eliminating the risk of potential high-dose related side effects and development of anti-Tocilizumab antibodies.
  • User friendly test protocol, ready to use reagents, short run time.
  • No reaction with any other proteins present in native human serum.
  • No reaction with the other therapeutic monoclonal antibodies.
  • The lowest detectable level that can be specifically distinguished from the zero standard is 10 ng/mL.

*These test kits are for Research Use Only

View our complete selection of Research Drug Monitoring ELISA assays:

Adalimumab (Humira®)
Adalimumab (Humira®) Control Set
Aflibercept (Eylea®, Zaltrap®)
Anti-Adalimumab (Humira®)
Anti-Adalimumab (Humira®) Confirmatory Reagent
Anti-Bevacizumab (Avastin®)
Anti-Certolizumab pegol (Cimzia®)
Anti-Cetuximab (Erbitux®)
Anti-Etanercept (Enbrel®)
Anti-Golimumab (Simponi®)
Anti-Infliximab (Remicade®) (ATI)
Anti-Infliximab (Remicade®) (Total)
Anti-Infliximab (Remicade®) Confirmatory Reagent
Anti-Nivolumab (Opdivo®)
Anti-Omalizumab (Xolair®)
Anti-Rituximab (Rituxan®)
Anti-Tocilizumab (Actemra®)
Anti-Trastuzumab (Herceptin®)
Anti-Vedolizumab (Entyvio®)
Anti-Ustekinumab (Stelara®)
Bevacizumab (Avastin®)
Bevacizumab (Avastin®) (mAb-based)
Certolizumab pegol (Cimzia®) (mAb-based)
Cetuximab (Erbitux®) (mAb-based)
Etanercept (Enbrel®)
Etanercept (Enbrel®) (mAb-based)
Golimumab (Simponi®)
Golimumab (Simponi®) (mAb-based)
Infliximab (Remicade®)
Infliximab (Remicade®) (mAb-based)
Infliximab (Remicade®) Control Set
Nivolumab (Opdivo®) (mAb-based)
Omalizumab (Xolair®) (mAb-based)
Ranibizumab (Lucentis®) (mAb-based)
Rituximab (Rituxan®) (mAb-based)
Tocilizumab (Actemra®) (mAb-based)
Trastuzumab (Herceptin®)
Trastuzumab (Herceptin®) (mAb-based)
Ustekinumab (Stelara®) (mAb-based)
Vedolizumab (Entyvio®) (mAb-based)

OUR ASSAY KIT CATEGORIES